Ignite Creation Date:
2025-12-24 @ 4:54 PM
Ignite Modification Date:
2025-12-24 @ 4:54 PM
Study NCT ID:
NCT06648850
Status:
NOT_YET_RECRUITING
Last Update Posted:
2025-05-23
First Post:
2024-10-17
Is Possible Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Clinical Study of DA-001 as a Treatment for Telogen Effluvium
Sponsor:
Applied Biology, Inc.
Organization:
Study Overview
Official Title:
Clinical Study of DA-001 as a Treatment for Telogen Effluvium
Status:
NOT_YET_RECRUITING
Status Verified Date:
2025-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objective of the study is to assess the safety and efficacy of DA-001 as a treatment for telogen effluvium
Detailed Description:
DA-001 is a topical alpha 1 agonist combined with a TAAR receptor agonist. DA-001 was studied in a population of women that suffer from excessive hair shedding. DA-001 demonstrated significant reduction in hair shedding.
This study aims to assess the safety and efficacy of DA-001 as a treatment for telogen effluvium.
This study aims to assess the safety and efficacy of DA-001 as a treatment for telogen effluvium.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?: